PMCF Study in Patients With Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated With E-vita OPEN NEO

N/AActive Not RecruitingNCT04986709

JOTEC GmbH114 enrolled

Overview

The NEOS-APAC post-market clinical follow-up study is undertaken to demonstrate the safety and clinical performance of E-vita OPEN NEO in the treatment of aneurysm or dissection in the ascending aorta, aortic arch and descending thoracic aorta.

In this study, patients will be observed who receive an E-vita OPEN NEO implant for the treatment of thoracic aneurysm or acute or chronic thoracic dissection. E-vita OPEN NEO will be implanted according to the instructions for use and at the discretion of the treating physician. Participating physicians will provide their observations collected during routine care for patients treated with E-vita OPEN NEO. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection. The period of data collection will be approximately 24 months from the date of intervention for each patient. Source data verification will be performed on 100% of the patients; data from all the visits that was provided in the database will be reviewed and verified against existing source documents. Complete DICOM image files of the CT scans will be sent to the CoreLab for independent evaluation.

Study Type

OBSERVATIONAL

Enrollment

114

Conditions

Aortic Dissection Aortic Aneurysm

Interventions

Open repairDEVICE

Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient´s age is between 18 and 75 years. * Patient is willing and able to comply with the standard follow-up visits planned after the implantation procedure. * Patient is willing and able to give informed consent. * Patient satisfies one of the following categories: * Patient has acute / subacute aortic dissection and requires repair or replacement of damaged or diseased vessels of the aortic arch (with or without involvement of the ascending aorta), and the descending aorta requires treatment, or, in the opinion of the investigator, the patient would derive clinical benefit from prophylactic treatment of the descending aorta. * Patient has chronic aortic dissection which requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta, and the patient satisfies one or more of the following criteria: Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥ 5.5 cm. Patient has aorta diameter \< 5.5 cm and a growth rate of ≥ 0.5 cm / year. Patient has ascending aorta diameter ≥ 4.5 cm and requires an aortic valve repair or replacement. Patient has clinical signs of abdominal or peripheral malperfusion. • Patient has a fusiform or saccular aortic aneurysm which requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta, and patient satisfies the following criteria: Patient has a suitable distal sealing area in the descending thoracic aorta proximal to the celiac trunk. And in case of fusiform aneurysm one of the following characteristics: Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥ 5.5 cm. Patient has aorta diameter \< 5.5 cm and a growth rate of ≥ 0.5 cm / year. Patient has ascending aorta diameter ≥ 4.5 cm and requires an aortic valve repair or replacement. • Patient is hemodynamically stable without pharmacological support at time of admission to the hospital (stable blood pressure and heart rate, no shock). Exclusion Criteria: * Patient is unfit for open surgical repair involving circulatory arrest. * Patient has known sensitivities or allergies to nitinol, polyester, platinumiridium, or polyethylene. * Patient has systemic infection. * Patient has endocarditis or active infection of the aorta. * Patient has a free ruptured aorta. * Patient has acute stroke or suspected acute stroke. * Patient is on inotropes at time of arrival to the hospital. * Patient needs mitral valve repair or replacement. * Patient is enrolled or plans to be enrolled in another active study. * Patient is pregnant or breastfeeding or planning to become pregnant during the course of the study. * Patient has uncorrectable bleeding anomaly (i.e., thrombocytopenia). * Patient has an eGFR \< 45 ml/min/1.73m2 before the intervention * Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated. * Patient has co-morbidity (i.e. active malignancy (progressive, stable or partial remission)) causing expected survival to be less than 3 years. * Patient has any other medical, social or psychological problems, that in the opinion of the investigator, preclude the patient from participating in this study.

Locations (10)

Austin Health

Heidelberg, Victoria, Australia

Prince of Wales Hospital (PWH)

Hong Kong, Hong Kong

Queen Mary Hospital

Hong Kong, Hong Kong

Queen Elizabeth Hospital II

Kota Kinabalu, Malaysia

Outcomes

Primary Outcomes

Mortality

Rate of all-cause mortality

Time frame: 30-day

Secondary Outcomes

Mortality

Rate of all-cause mortality

Time frame: 3-6, 12, 24 months

Mortality

Rate of aortic related mortality

Time frame: 30-day, 3-6, 12, 24 months

Major Adverse Events

Rate of patients who are free from Major Adverse Events (MAEs) (new permanent disabling stroke (mRS ≥ 2 and at baseline mRS \< 2), new permanent (\> 30 days) paraplegia or paraparesis, reintervention (excluding reoperation for bleeding or planned or unplanned additional intervention), all-cause mortality)

Time frame: 12 months

Device technical success

Rate of patients with device technical success

Time frame: 24 hours

Procedural success

Rate of patients with procedural success

Time frame: At discharge, an avarage of 30 days

Treatment success

Rate of patients with treatment success

Time frame: At discharge, an avarage of 30 days, 3-6,12, 24 months

Aortic rupture

Rate of patients with aortic rupture

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Institut Jantung Negara

Kuala Lumpur, Malaysia

National University Hospital

Singapore, Singapore

Seoul National University Bundang Hospital

Seongnam, South Korea

Ewha Womans University Seoul Hospital

Seoul, South Korea

Gangnam Severance Hospital

Seoul, South Korea

Siriraj Hospital

Bangkok, Thailand

Additional intervention

Rate of patients with planned or unplanned additional intervention

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Reintervention

Rate of patients with reintervention

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Disabling stroke

Rate of patients with new disabling stroke

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Paraplegia

Rate of patients with new permanent (\> 30 days) paraplegia

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Paraparesis

Rate of patients with new permanent (\> 30 days) paraparesis

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Renal failure

Rate of patients with renal failure requiring permanent (\> 90 days) dialysis or hemofiltration in a patient with a normal pre-procedure serum creatinine level

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Aortic regurgitation

Rate of patients with increase in aortic regurgitation grade of greater than 1 compared to pre-operative measurement

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Stenosis

Rate of patients with stenosis in the supra-aortic head vessels (0 - 30 %, \>30 % - 50 %, \> 50 % - 70%, \> 70%)

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Patency

Rate of patients with patent supra-aortic head vessels

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Migration

Rate of patients with retrograde migration \> 10 mm of the distal end of the stented part of E-vita OPEN NEO

Time frame: 3-6, 12, 24 months

Integrity

Rate of patients with failure of integrity of the E-vita OPEN NEO

Time frame: At discharge, an avarage of 30 days, 3-6, 12, 24 months

Endoleak type Ib (aneurysm)

Rate of patients with aneurysm that have an endoleak type Ib

Time frame: 3-6, 12, 24 months

Endoleak type II (aneurysm)

Rate of patients with aneurysm that have an endoleak type II

Time frame: 3-6, 12, 24 months

Endoleak type III (aneurysm)

Rate of patients with aneurysm that have an endoleak type III

Time frame: 3-6, 12, 24 months

Endoleak type IV (aneurysm)

Rate of patients with aneurysm that have an endoleak type IV

Time frame: 3-6, 12, 24 months

Increasing aortic diameter

Rate of patients with aneurysm that have an increasing maximum aortic diameter in the stented region (E-vita OPEN NEO) compared to first post-operative CT

Time frame: 3-6, 12, 24 months

Stable aortic diameter

Rate of patients with aneurysm that have a stable maximum aortic diameter in the stented region (E-vita OPEN NEO) compared to first post-operative CT

Time frame: 3-6, 12, 24 months

Decreasing aortic diameter

Rate of patients with aneurysm that have a decreasing maximum aortic diameter in the stented region (E-vita OPEN NEO) compared to first post-operative CT

Time frame: 3-6, 12, 24 months

Endoleak type Ib (dissection)

Rate of patients with dissection that have an endoleak type Ib

Time frame: 3-6, 12, 24 months

Endoleak II (dissection)

Rate of patients with dissection that have an endoleak type II

Time frame: 3-6, 12, 24 months

Endoleak type R (dissection)

Rate of patients with dissection that have an endoleak type R

Time frame: 3-6, 12, 24 months

Increasing or stable true lumen size

Rate of patients with increasing (≥ 5 mm) or stable true lumen in the stented region

Time frame: 3-6, 12, 24 months

Stable or decreasing false lumen size

Rate of patients with stable or decreasing (≤ - 5 mm) false lumen in the stented region

Time frame: 3-6, 12, 24 months

Obliterated false lumen in stented region

Rate of patients with obliterated false lumen in the stented region

Time frame: 3-6, 12, 24 months

Completely thrombosed false lumen in stented region

Rate of patients with completely thrombosed false lumen in the stented region

Time frame: 3-6, 12, 24 months

Partially thrombosed false lumen in stented region

Rate of patients with partially thrombosed false lumen in the stented region

Time frame: 3-6, 12, 24 months

Patent false lumen in stented region

Rate of patients with patent false lumen in the stented region

Time frame: 3-6, 12, 24 months

Obliterated false lumen between stent and celiac trunk

Rate of patients with obliterated false lumen between the bottom of the stent and the celiac trunk

Time frame: 3-6, 12, 24 months

Completely thrombosed false lumen between stent and celiac trunk

Rate of patients with completely thrombosed false lumen between the bottom of the stent and the celiac trunk

Time frame: 3-6, 12, 24 months

Partially thrombosed false lumen between stent and celiac trunk

Rate of patients with partially thrombosed false lumen between the bottom of the stent and the celiac trunk

Time frame: Time Frame: 3-6, 12, 24 months

Patent false lumen between stent and celiac trunk

Rate of patients with patent false lumen between the bottom of the stent and the celiac trunk

Time frame: 3-6, 12, 24 months

Obliterated false lumen between celiac trunk and aortic bifurcation

Rate of patients with obliterated false lumen between the celiac trunk and the aortic bifurcation

Time frame: 3-6, 12, 24 months

Completely thrombosed false lumen between celiac trunk and aortic bifurcation

Rate of patients with completely thrombosed false lumen between the celiac trunk and the aortic bifurcation

Time frame: 3-6, 12, 24 months

Partially thrombosed false lumen between celiac trunk and aortic bifurcation

Rate of patients with partially thrombosed false lumen between the celiac trunk and the aortic bifurcation

Time frame: 3-6, 12, 24 months

Patent false lumen between celiac trunk and aortic bifurcation

Rate of patients with patent false lumen between the celiac trunk and the aortic bifurcation

Time frame: 3-6, 12, 24 months